Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study

By sjmartinez • March 30, 2025

Yoo C, Ueno M, Klümpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park JO, Valle JW, Edeline J, Kim JG, Kamble S, Norquist JM, Yu L, Malhotra U, Finn RS. Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. J Hepatol. 2025 Mar 26:S0168-8278(25)00207-7. doi: 10.1016/j.jhep.2025.03.019. Epub ahead of print. PMID: 40154623.

Tags: biliary tract neoplasms, cisplatin, gemcitabine, Hematology/Oncology, immune checkpoint inhibitors, Patient reported outcome measures, pembrolizumab, Publications, Quality of Life

COVID-19 Pandemic and Posttreatment Breast Cancer Surveillance and Outcomes

Hahn EE, Eng S, Chen A, Haupt EC, Goodall S, Munoz-Plaza CE, Nguyen HQ, Gould MK, Ganz PA, Shen E. COVID-19 Pandemic and Posttreatment Breast[...]

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

Armand P, Zinzani PL, Timmerman JM, Johnson NA, Lavie D, Thiagarajan K, Topp B, Pillai PM, Herrera AF. Estimating efficacy of favezelimab plus pembrolizumab relative[...]

Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair

Hollowed J, Woo H, Hamburg S, Ardehali A. Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair. Tex Heart Inst J. 2025 Jul[...]